149 related articles for article (PubMed ID: 11696019)
1. Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate.
Aktas O; Ari N; Rieks M; Hoffmann V; Schimrigk S; Przuntek H; Pöhlau D
Acta Neurol Scand; 2001 Nov; 104(5):266-70. PubMed ID: 11696019
[TBL] [Abstract][Full Text] [Related]
2. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.
Ruggieri M; Avolio C; Scacco S; Pica C; Lia A; Zimatore GB; Papa S; Livrea P; Trojano M
J Neurol; 2006 Feb; 253(2):231-6. PubMed ID: 16184340
[TBL] [Abstract][Full Text] [Related]
4. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate.
Skihar V; Silva C; Chojnacki A; Döring A; Stallcup WB; Weiss S; Yong VW
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17992-7. PubMed ID: 19815532
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate.
Rieks M; Hoffmann V; Aktas O; Juschka M; Spitzer I; Brune N; Schimrigk S; Przuntek H; Pöhlau D
Eur Neurol; 2003; 50(4):200-6. PubMed ID: 14634263
[TBL] [Abstract][Full Text] [Related]
6. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein.
Dabbert D; Rösner S; Krämer M; Schöll U; Tumani H; Mäder M; Weber F
Neurosci Lett; 2000 Aug; 289(3):205-8. PubMed ID: 10961665
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
9. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis.
Chabot S; Yong FP; Le DM; Metz LM; Myles T; Yong VW
Mult Scler; 2002 Aug; 8(4):299-306. PubMed ID: 12166500
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
Ragheb S; Abramczyk S; Lisak D; Lisak R
Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
[TBL] [Abstract][Full Text] [Related]
13. Recent insights into the mechanism of action of glatiramer acetate.
Kala M; Miravalle A; Vollmer T
J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
Karussis D; Teitelbaum D; Sicsic C; Brenner T;
J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
Dhib-Jalbut S
Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R
Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
Arbour N; Rastikerdar E; McCrea E; Lapierre Y; Dörr J; Bar-Or A; Antel JP
Mult Scler; 2005 Dec; 11(6):652-7. PubMed ID: 16320724
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.
Weber MS; Starck M; Wagenpfeil S; Meinl E; Hohlfeld R; Farina C
Brain; 2004 Jun; 127(Pt 6):1370-8. PubMed ID: 15090474
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
